Updated Molecular Imaging Software with Centiloid Scale Quantification Gets FDA Nod
The latest edition of the Hermia software reportedly facilitates standard evaluation of amyloid PET quantification across a variety of tracers and protocols.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated molecular imaging software Hermia, which includes Centiloid scaling for quantification of amyloid positron emission tomography (PET) imaging.
Through the integration of the Centiloid scale, the Hermia software Hernia software enables amyloid quantification for multiple PET tracers and protocols, according to Hermes Medical Solutions, the manufacturer of the software.
“We are excited to bring the Centiloid scale into the USA with this clearance, and to make further standardizations closer to our users and their patients. Standardizations such as this help to move our field forward in early diagnostic and novel treatment for Alzheimer’s disease which poses immense threat for globally aging population.” said Tom Francke, the CEO of Hermes Medical Solutions.
The updated Hermia software also enables simultaneous displays of hyper- and hypometabolism regions on FDG brain scans as well as extended visualization and comparison capabilities for assessing 3D digital SPECT/CT images, according to Hermes Medical Solutions.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
